ArticleEBioMedicine2022

Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.

Kiminori Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.